Eisai rebounds after lecanemab subcutaneous formulation approved in China as initial therapy for early AD
Eisai Co., Ltd. <4523> rebounded after announcing in the afternoon that a subcutaneous formulation of Leqembi (generic name: lecanemab), co-developed with Biogen
Source: MINKABU PRESS
*Translated by generative AI. Click here for the original article.
Related Articles
-
Market breadth at 2 p.m.: 954 gainers vs. 538 decliners on TSE Prime
Thu Sep 3, 2026 2:04 pm JST Market -
NIPPON PAINT HOLDINGS rebounds for first time in three sessions as domestic brokerage raises target price to 1,550 yen
Thu Sep 3, 2026 1:46 pm JST Catalyst -
INPEX extends losses as WTI crude briefly falls below $91 in after-hours trading
Thu Sep 3, 2026 1:39 pm JST Catalyst -
unbanked ranks 5th in 'rising buy forecasts' among individual investors on Minkabu
Thu Sep 3, 2026 1:35 pm JST Catalyst -
ASAHI extends losses as August same-store sales fall for second straight month
Thu Sep 3, 2026 1:29 pm JST Catalyst -
Market breadth at 1 p.m.: 978 gainers vs. 509 decliners on TSE Prime
Thu Sep 3, 2026 1:04 pm JST Market -
EXTREME rebounds as subsidiary to make world premiere of new 'Lollipop Chainsaw' title at TGS
Thu Sep 3, 2026 1:01 pm JST Catalyst -
JTEKT rises to 5th place in 'rising buy forecasts' ranking on Minkabu
Thu Sep 3, 2026 12:53 pm JST Catalyst -
and ST HD rebounds after 6 sessions as August same-store sales rise for second straight month
Thu Sep 3, 2026 12:41 pm JST Catalyst -
Tokyo stocks: Nikkei average widens gains at afternoon session open
Thu Sep 3, 2026 12:31 pm JST Market